Legal & General Group PLC Novavax Inc Transaction History

Legal & General Group PLC

  • $431 Billion
  • Q3 2025

A detailed history of Legal & General Group PLC transactions in Novavax Inc stock. As of the latest transaction made, Legal & General Group PLC holds 155,743 shares of NVAX stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155,743
Previous 154,214 0.99%
Holding current value
$1.09 Million
Previous $971,000 39.03%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
BUY
$6.56 - $9.71 $10,030 - $14,846
1,529 Added 0.99%
155,743 $1.35 Million
Q2 2025

Aug 12, 2025
BUY
$5.43 - $7.74 $526 - $750
97 Added 0.06%
154,214 $971,000
Q1 2025

May 15, 2025
BUY
$6.41 - $10.82 $38,838 - $65,558
6,059 Added 4.09%
154,117 $987,000
Q4 2024

Feb 13, 2025
SELL
$7.22 - $14.68 $223 - $455
-31 Reduced 0.02%
148,058 $1.19 Million
Q3 2024

Feb 28, 2025
SELL
$10.71 - $17.11 $139,829 - $223,388
-13,056 Reduced 8.82%
135,002 $1.71 Million
Q3 2024

Nov 14, 2024
BUY
$10.71 - $17.11 $4,069 - $6,501
380 Added 0.26%
148,089 $1.87 Million
Q2 2024

May 29, 2025
BUY
$3.89 - $20.97 $85,544 - $461,151
21,991 Added 19.52%
134,622 $1.7 Million
Q2 2024

Aug 14, 2024
BUY
$3.89 - $20.97 $136,453 - $735,585
35,078 Added 31.14%
147,709 $1.87 Million
Q1 2024

May 29, 2025
SELL
$3.76 - $6.02 $155,987 - $249,745
-41,486 Reduced 26.92%
112,631 $538,000
Q1 2024

Jul 01, 2024
BUY
$3.76 - $6.02 $24,455 - $39,154
6,504 Added 6.13%
112,631 $538,000
Q1 2024

May 14, 2024
BUY
$3.76 - $6.02 $25,500 - $40,827
6,782 Added 6.83%
106,127 $507,000
Q4 2023

May 29, 2025
SELL
$4.8 - $7.67 $262,905 - $420,101
-54,772 Reduced 35.54%
99,345 $476,000
Q4 2023

Feb 15, 2024
BUY
$4.8 - $7.67 $12,753 - $20,379
2,657 Added 2.75%
99,345 $476,000
Q3 2023

Nov 14, 2023
SELL
$6.81 - $9.74 $62,495 - $89,383
-9,177 Reduced 8.67%
96,688 $700,000
Q2 2023

Aug 14, 2023
BUY
$6.67 - $9.52 $262,891 - $375,221
39,414 Added 59.31%
105,865 $786,000
Q1 2023

May 15, 2023
SELL
$5.76 - $12.48 $28,373 - $61,476
-4,926 Reduced 6.9%
66,451 $460,000
Q4 2022

Feb 14, 2023
SELL
$8.86 - $25.04 $27,306 - $77,173
-3,082 Reduced 4.14%
71,377 $733,000
Q3 2022

Nov 14, 2022
SELL
$18.2 - $76.12 $131,258 - $548,977
-7,212 Reduced 8.83%
74,459 $1.36 Million
Q2 2022

Aug 22, 2022
SELL
$36.28 - $75.29 $5.74 Million - $11.9 Million
-158,083 Reduced 65.94%
81,671 $4.2 Million
Q1 2022

May 16, 2022
BUY
$69.73 - $142.9 $1.53 Million - $3.14 Million
21,947 Added 10.08%
239,754 $17.7 Million
Q4 2021

Feb 14, 2022
SELL
$134.56 - $217.97 $1.88 Million - $3.04 Million
-13,956 Reduced 6.02%
217,807 $31.2 Million
Q3 2021

Nov 15, 2021
BUY
$177.8 - $270.58 $480,771 - $731,648
2,704 Added 1.18%
231,763 $48 Million
Q2 2021

Aug 12, 2021
BUY
$121.0 - $257.67 $22.3 Million - $47.5 Million
184,500 Added 414.06%
229,059 $48.6 Million
Q1 2021

May 17, 2021
BUY
$112.98 - $319.93 $450,564 - $1.28 Million
3,988 Added 9.83%
44,559 $8.08 Million
Q4 2020

Feb 12, 2021
BUY
$78.74 - $139.5 $421,888 - $747,441
5,358 Added 15.22%
40,571 $4.53 Million
Q3 2020

Nov 13, 2020
BUY
$79.44 - $178.51 $1.65 Million - $3.71 Million
20,767 Added 143.76%
35,213 $3.82 Million
Q2 2020

Aug 14, 2020
BUY
$13.86 - $83.61 $123,949 - $747,724
8,943 Added 162.51%
14,446 $1.2 Million
Q1 2020

May 14, 2020
SELL
$3.93 - $16.0 $903 - $3,680
-230 Reduced 4.01%
5,503 $75,000
Q4 2019

Feb 13, 2020
SELL
$3.69 - $5.22 $1,523 - $2,155
-413 Reduced 6.72%
5,733 $23,000
Q3 2019

Nov 13, 2019
BUY
$4.02 - $7.84 $4,036 - $7,871
1,004 Added 19.53%
6,146 $31,000
Q2 2019

Aug 14, 2019
BUY
$4.93 - $12.2 $25,350 - $62,732
5,142 New
5,142 $32,000

Others Institutions Holding NVAX

# of Institutions
310
Shares Held
95.7M
Call Options Held
5.7M
Put Options Held
9.06M
View Full List

About NOVAVAX INC

NVAX Quotes by TradingView
  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $545M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email